Ground-breaking research by BHP members has discovered a new technique to assess how aggressively a child’s brain tumour is likely to develop.
Funded by Children with Cancer UK, Action Medical Research and The Brain Tumour Charity, the study is the first of its kind and will allow clinicians to give more personalised treatments for childhood brain cancers, which currently account for 1/3 of all childhood cancer deaths in the UK.
Researchers took biopsies of childhood brain tumours over five years to study their chemical make-up in high precision.
They found that the level of lipids and glutamine a tumour contained were direct indicators of how aggressive it would be. The more glutamine a tumour contains, the less aggressive it is likely to be, while a tumour containing more lipids is likely to be more aggressive.
The study also found a non-invasive technique can be used to measure these concentrations in higher precision than is currently being done in routine clinical practice. Clinicians can simply put patients through an MRI scanner, then use a Magnetic Resonance Spectroscopy (MRS) to determine the levels of glutamine and lipids in the tumour.
Introducing this method across UK clinical practice will help increase survival rates for children receiving treatment for brain tumours. This non-invasive approach specifically benefits young patients with tumours in high-risk areas, such as the brain stem, who may not ordinarily undergo a biopsy due to the sensitive location.
It will also enable clinicians to have a more accurate understanding of each individual tumour’s aggressiveness and to tailor treatments accordingly, so that they are only as toxic as they need to be.
Andrew Peet, research lead at the Children’s Brain Tumour Research Team and Professor of Clinical Paediatric Oncology at BHP founder members the University of Birmingham and Birmingham Children’s Hospital, said: “This study is a huge step forwards towards the introduction of more personalised treatment for childhood brain tumour patients.
“Assessing how aggressive these tumours are at an earlier stage will help ensure that treatment is no more toxic than it needs to be, reducing the adverse effects on patients and improving their quality of life.”
Acting CEO of Children with Cancer UK Mark Brider, commented: “Childhood cancers are very different to those found in adults, as they are often more difficult to treat and the treatment can be incredibly debilitating.
“Brain tumours are among the most common childhood tumours and I am very pleased to see developments being made to make treatment less toxic. Children with Cancer UK helps fund childhood cancer research projects like the University of Birmingham’s study in order to improve survival rates and outcomes so that children don’t have to suffer long-term effects from treatment.”